Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism

Table 1

Demographic and TNF-alpha (pg/ml) data for study subjects.

ID	Age	Completed	Baseline TNF-alpha (pg/ml)		Week 12 TNF-alpha (pg/ml)
			CSF	Serum	CSF	Serum
1	7	Y	103	74	24	20
2	12	Y	19^*	14^*	5^*	8^*
3	7	Y	101	15^*	78	54
4	11	Y	99	102	45	27
5	8	N	157	180		106
6	6	N	232	165
7	8	N	55	58
𝑃 value^*†					0.068	0.068

^* 1: 1 diluted samples.
^†𝑃 values represent the results of the differences between baseline values and 6 and 12-month values using the Wilcoxon Signed Ranks Test.